The company have informed us that they are no longer seeking regulatory approval in this indication. Therefore the appraisal is suspended.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 721 |
| Referral date | 01 July 2014 |
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | TBC |
Project Team
| Associate Director: | Janet Robertson |
| Communications manager: | Alice Law |
| Project manager: | Bijal Joshi |
| Technical Advisor: | TBC |
| Technical Lead: | TBC |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 26 August 2022 | Discontinued. The company have informed us that they are no longer seeking regulatory approval in this indication. Therefore the appraisal is suspended. |
| 15 January 2018 | Suspended. The company have advised that they will not be pursuing a licensing application for ipilimumab from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal on its work programme. As this appraisal has been referred to NICE we will continue to monitor any development and will update interested parties if the situation changes. |
| July 2014 | Following on from advice received from the manufacturer, the dates for this appraisal will be confirmed once regulatory approval timelines are established. |
For further information on our processes and methods, please see our CHTE processes and methods manual